NY-ESO-1: Review of an Immunogenic Tumor Antigen

Advances in Cancer Research

Volumn 95, Issue , 2006, Pages 1-30

  Gnjatic, Sacha ^a   Nishikawa, Hiroyoshi ^a   Jungbluth, Achim A ^a   Güre, Ali O ^a   Ritter, Gerd ^a   Jäger, Elke ^b   Knuth, Alexander ^c   Chen, Yao Tseng ^d   Old, Lloyd J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b KRANKENHAUS NORDWEST   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER VACCINE; DNA VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NY ESO 1 ANTIGEN; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ACROSOME; AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER STAGING; CANCER TESTIS ANTIGEN NY ESO 1 GENE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHROMOSOME ANALYSIS; CHROMOSOME XQ; CLINICAL TRIAL; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; ESOPHAGUS CANCER; FOWLPOX VIRUS; GENE; GENE EXPRESSION; GENE LOCATION; GENE MAPPING; HEAD AND NECK CANCER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PREGNANCY; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; RNA INTERFERENCE; SEX ROLE; STOMACH CANCER; SYNOVIAL SARCOMA; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; TUMOR IMMUNITY; VACCINATION; VACCINIA; VIRUS RECOMBINANT; X CHROMOSOME;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CLINICAL TRIALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTES; MALE; MEMBRANE PROTEINS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33746211234     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(06)95001-5     Document Type: Review

References (109)

1. Aarnoudse C.A., van den Doel P.B., Heemskerk B., and Schrier P.I. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int. J. Cancer 82 (1999) 442-448
2. Akcakanat A., Kanda T., Koyama Y., Watanabe M., Kimura E., Yoshida Y., Komukai S., Nakagawa S., Odani S., Fujii H., and Hatakeyama K. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother. Pharmacol. 54 (2004) 95-100
3. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
4. Alpen B., Güre A.O., Scanlan M.J., Old L.J., and Chen Y.T. A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. Gene 297 (2002) 141-149
5. Atanackovic D., Matsuo M., Ritter E., Mazzara G., Ritter G., Jäger E., Knuth A., Old L.J., and Gnjatic S. Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. J. Immunol. Methods 278 (2003) 57-66
6. Ayyoub M., Taub R.N., Keohan M.L., Hesdorffer M., Metthez G., Memeo L., Mansukhani M., Hibshoosh H., Hesdorffer C.S., and Valmori D. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun. 4 (2004) 7
7. Benlalam H., Labarriere N., Linard B., Derre L., Diez E., Pandolfino M.C., Bonneville M., and Jotereau F. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): Implications for immunotherapy. Eur. J. Immunol. 31 (2001) 2007-2015
8. Bensinger S.J., Bandeira A., Jordan M.S., Caton A.J., and Laufer T.M. Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells. J. Exp. Med. 194 (2001) 427-438
9. Bolli M., Schultz-Thater E., Zajac P., Guller U., Feder C., Sanguedolce F., Carafa V., Terracciano L., Hudolin T., Spagnoli G.C., and Tornillo L. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: A tissue microarray study. Int. J. Cancer 115 (2005) 960-966
10. Chen H.S., Qin L.L., Cong X., Wang Y., Fei R., Jiang D., Cao J., Su J.J., Wei L., Chen W.F., and Wang Y. Expression of tumor-specific cancer/testis antigens in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 11 (2003) 145-148
11. Chen J.-L., Dunbar P.R., Gileadi U., Jäger E., Gnjatic S., Nagata Y., Stockert E., Panicali D.L., Chen Y.-T., Knuth A., Old L.J., and Cerundolo V. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 165 (2000) 948-955
12. Chen J.-L., Stewart-Jones G., Bossi G., Lissin N.M., Wooldridge L., Choi E.M., Held G., Dunbar P.R., Esnouf R.M., Sami M., Boulter J.M., Rizkallah P., et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201 (2005) 1243-1255
13. Chen Q., Jackson H., Parente P., Luke T., Rizkalla M., Tai T.Y., Zhu H.C., Mifsud N.A., Dimopoulos N., Masterman K.A., Hopkins W., Goldie H., et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc. Natl. Acad. Sci. USA 101 (2004) 9363-9368
14. Chen Q., Jackson H., Shackleton M., Parente P., Hopkins W., Sturrock S., MacGregor D., Maraskovsky E., Tai T.Y., Dimopoulos N., Masterman K.A., Luke T., et al. Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immun. 5 (2005) 5
15. Chen Y.-T., Scanlan M.J., Sahin U., Türeci O., Güre A.O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., and Old L.J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94 (1997) 1914-1918
16. Cilensek Z.M., Yehiely F., Kular R.K., and Deiss L.P. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, interferon-gamma, taxol and gamma-irradiation. Cancer Biol. Ther. 1 (2002) 380-387
17. Danke N.A., Koelle D.M., Yee C., Beheray S., and Kwok W.W. Autoreactive T cells in healthy individuals. J. Immunol. 172 (2004) 5967-5972
18. Davis I.D., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., Chen Q., Dimopoulos N., Luke T., Murphy R., Scott A.M., Maraskovsky E., et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl. Acad. Sci. USA 101 (2004) 10697-10702
19. De Smet C., De Backer O., Faraoni I., Lurquin C., Brasseur F., and Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Sci. USA 93 (1996) 7149-7153
20. Dhodapkar M.V., Osman K., Teruya-Feldstein J., Filippa D., Hedvat C.V., Iversen K., Kolb D., Geller M.D., Hassoun H., Kewalramani T., Comenzo R.L., Coplan K., et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 3 (2003) 9
21. Dutoit V., Rubio-Godoy V., Doucey M.A., Batard P., Lienard D., Rimoldi D., Speiser D., Guillaume P., Cerottini J.C., Romero P., and Valmori D. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J. Immunol. 168 (2002) 1167-1171
22. Dutoit V., Taub R.N., Papadopoulos K.P., Talbot S., Keohan M.L., Brehm M., Gnjatic S., Harris P.E., Bisikirska B., Guillaume P., Cerottini J.C., Hesdorffer C.S., et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J. Clin. Invest. 110 (2002) 1813-1822
23. Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., and Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122 (2005) 835-847
24. Fossa A., Berner A., Fossa S.D., Hernes E., Gaudernack G., and Smeland E.B. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 59 (2004) 440-447
25. Fujita S., Wada H., Jungbluth A.A., Sato S., Nakata T., Noguchi Y., Doki Y., Yasui M., Sugita Y., Yasuda T., Yano M., Ono T., et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin. Cancer Res. 10 (2004) 6551-6558
26. Gaugler B., Van den Eynde B., van der Bruggen P., Romero P., Gaforio J.J., De Plaen E., Lethé B., Brasseur F., and Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179 (1994) 921-930
27. Gnjatic S., Nagata Y., Jäger E., Stockert E., Shankara S., Roberts B.L., Mazzara G.P., Lee S.Y., Dunbar P.R., Dupont B., Cerundolo V., Ritter G., et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl. Acad. Sci. USA 97 (2000) 10917-10922
28. Gnjatic S., Jäger E., Chen W., Altorki N.K., Matsuo M., Lee S.Y., Chen Q., Nagata Y., Atanackovic D., Chen Y.T., Ritter G., Cebon J., et al. CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc. Natl. Acad. Sci. USA 99 (2002) 11813-11818
29. Gnjatic S., Atanackovic D., Jager E., Matsuo M., Selvakumar A., Altorki N.K., Maki R.G., Dupont B., Ritter G., Chen Y.T., Knuth A., and Old L.J. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proc. Natl. Acad. Sci. USA 100 (2003) 8862-8867
30. Gnjatic S., Atanackovic D., Matsuo M., Jäger E., Lee S.-Y., Valmori D., Chen Y.T., Ritter G., Knuth A., and Old L.J. Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J. Immunol. 170 (2003) 1191-1196
31. Gotter J., Brors B., Hergenhahn M., and Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199 (2004) 155-166
32. Güre A.O., Chua R., Williamson B., Gonen M., Ferrera C.A., Gnjatic S., Ritter G., Simpson A.J., Chen Y.T., Old L.J., and Altorki N.K. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin. Cancer Res. 11 (2005) 8055-8062
33. Huarte E., Karbach J., Gnjatic S., Bender A., Jager D., Arand M., Atanackovic D., Skipper J., Ritter G., Chen Y.T., Old L.J., Knuth A., et al. HLA-DP4 expression and immunity to NY-ESO-1: Correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. Cancer Immun. 4 (2004) 15
34. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., and Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188 (1998) 2357-2368
35. Jordan M.S., Boesteanu A., Reed A.J., Petrone A.L., Holenbeck A.E., Lerman M.A., Naji A., and Caton A.J. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2 (2001) 301-306
36. Jungbluth A.A., Antonescu C.R., Busam K.J., Iversen K., Kolb D., Coplan K., Chen Y.T., Stockert E., Ladanyi M., and Old L.J. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int. J. Cancer 94 (2001) 252-256
37. Jungbluth A.A., Busam K.J., Iversen K., Kolb D., Coplan K., Chen Y.-T., Stockert E., Zhang P.J., Old L.J., and Nelson P.T. Meeting abstract. Mod. Pathol. 14 (2001) 211A
38. Jungbluth A.A., Chen Y.T., Stockert E., Busam K.J., Kolb D., Iversen K., Coplan K., Williamson B., Altorki N., and Old L.J. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int. J. Cancer 92 (2001) 856-860
39. Jungbluth A.A., Iversen K., Kolb D., Coplan K., Chen Y.T., Stockert E., Old L.J., and Vogel M. Meeting abstract. Pathol. Res. Pract. 197 (2001) 218
40. Juretic A., Spagnoli G.C., Schultz-Thater E., and Sarcevic B. Cancer/testis tumour-associated antigens: Immunohistochemical detection with monoclonal antibodies. Lancet Oncol. 4 (2003) 104-109
41. Jäger D., Stockert E., Karbach J., Herrlinger K., Atmaca A., Arand M., Chen Y.T., Gnjatic S., Old L.J., Knuth A., and Jäger E. Urine antibody against human cancer antigen NY-ESO-1. Cancer Immun. 2 (2002) 10
42. Jäger E., Chen Y.-T., Drijfhout J.W., Karbach J., Ringhoffer M., Jäger D., Arand M., Wada H., Noguchi Y., Stockert E., Old L.J., and Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187 (1998) 265-270
43. Jäger E., Stockert E., Zidianakis Z., Chen Y.-T., Karbach J., Jäger D., Arand M., Ritter G., Old L.J., and Knuth A. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: Correlation with clinical events. Int. J. Cancer 84 (1999) 506-510
44. Jäger E., Gnjatic S., Nagata Y., Stockert E., Jäger D., Karbach J., Neumann A., Rieckenberg J., Chen Y.-T., Ritter G., Hoffman E., Arand M., et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. USA 97 (2000) 12198-12203
45. Jäger E., Jäger D., Karbach J., Chen Y.-T., Ritter G., Nagata Y., Gnjatic S., Stockert E., Arand M., Old L.J., and Knuth A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 191 (2000) 625-630
46. Jäger E., Nagata Y., Gnjatic S., Wada H., Stockert E., Karbach J., Dunbar P.R., Lee S.Y., Jungbluth A., Jager D., Arand M., Ritter G., et al. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA 97 (2000) 4760-4765
47. Jäger E., Karbach J., Gnjatic S., Jäger D., Maeurer M., Atmaca A., Arand M., Skipper J., Stockert E., Chen Y.-T., Old L.J., and Knuth A. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immun. 2 (2002) 12
48. Kaech S.M., and Ahmed R. CD8 T cells remember with a little help. Science 300 (2003) 263-265
49. Khong H.T., Yang J.C., Topalian S.L., Sherry R.M., Mavroukakis S.A., White D.E., and Rosenberg S.A. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother. 27 (2004) 472-477
50. Konishi J., Toyooka S., Aoe M., Omura Y., Washio K., Tsukuda K., and Shimizu N. The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer. Oncol. Rep. 11 (2004) 1063-1067
51. Korangy F., Ormandy L.A., Bleck J.S., Klempnauer J., Wilkens L., Manns M.P., and Greten T.F. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin. Cancer Res. 10 (2004) 4332-4341
52. Kubuschok B., Xie X., Jesnowski R., Preuss K.D., Romeike B.F., Neumann F., Regitz E., Pistorius G., Schilling M., Scheunemann P., Izbicki J.R., Lohr J.M., et al. Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int. J. Cancer 109 (2004) 568-575
53. Kurashige T., Noguchi Y., Saika T., Ono T., Nagata Y., Jungbluth A., Ritter G., Chen Y.T., Stockert E., Tsushima T., Kumon H., Old L.J., et al. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade. Cancer Res. 61 (2001) 4671-4674
54. Le Gal F.A., Ayyoub M., Dutoit V., Widmer V., Jager E., Cerottini J.C., Dietrich P.Y., and Valmori D. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. J. Immunother. 28 (2005) 252-257
55. Lethé B., Lucas S., Michaux L., De Smet C., Godelaine D., Serrano A., De Plaen E., and Boon T. LAGE-1, a new gene with tumor specificity. Int. J. Cancer 76 (1998) 903-908
56. Li M., Yuan Y.H., Han Y., Liu Y.X., Yan L., Wang Y., and Gu J. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin. Cancer Res. 11 (2005) 1809-1814
57. Mandic M., Almunia C., Vicel S., Gillet D., Janjic B., Coval K., Maillere B., Kirkwood J.M., and Zarour H.M. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res. 63 (2003) 6506-6515
58. Mandic M., Castelli F., Janjic B., Almunia C., Andrade P., Gillet D., Brusic V., Kirkwood J.M., Maillere B., and Zarour H.M. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol. 174 (2005) 1751-1759
59. Mashino K., Sadanaga N., Tanaka F., Yamaguchi H., Nagashima H., Inoue H., Sugimachi K., and Mori M. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br. J. Cancer 85 (2001) 713-720
60. Matsuo M., Nagata Y., Sato E., Atanackovic D., Valmori D., Chen Y.T., Ritter G., Mellman I., Old L.J., and Gnjatic S. IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc. Natl. Acad. Sci. USA 101 (2004) 14467-14472
61. Murphy R., Green S., Ritter G., Cohen L., Ryan D., Woods W., Rubira M., Cebon J., Davis I.D., Sjolander A., Kypridis A., Kalnins H., et al. Recombinant NY-ESO-1 cancer antigen: Production and purification under cGMP conditions. Prep. Biochem. Biotechnol. 35 (2005) 119-134
62. Nagata Y., Ono S., Matsuo M., Gnjatic S., Valmori D., Ritter G., Garrett W., Old L.J., and Mellman I. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc. Natl. Acad. Sci. USA 99 (2002) 10629-10634
63. Nakada T., Noguchi Y., Satoh S., Ono T., Saika T., Kurashige T., Gnjatic S., Ritter G., Chen Y.T., Stockert E., Nasu Y., Tsushima T., et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun. 3 (2003) 10
64. Nelson P.T., Jungbluth A.A., Old L.J., Iversen K., Weidner N., Spagnoli G.C.C.K., Tomaszewski J.E., Praha T.L., and Zhang P.J. Meeting abstract. Mod. Pathol. 14 (2001)
65. Neumann F., Wagner C., Kubuschok B., Stevanovic S., Rammensee H.G., and Pfreundschuh M. Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol. Immunother. 53 (2004) 589-599
66. Nishikawa H., Jager E., Ritter G., Old L.J., and Gnjatic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 106 (2005) 1008-1011
67. Nishikawa H., Kato T., Tawara I., Saito K., Ikeda H., Kuribayashi K., Allen P.M., Schreiber R.D., Sakaguchi S., Old L.J., and Shiku H. Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J. Exp. Med. 201 (2005) 681-686
68. Nishikawa H., Kato T., Tawara I., Takemitsu T., Saito K., Wang L., Ikarashi Y., Wakasugi H., Nakayama T., Taniguchi M., Kuribayashi K., Old L.J., et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA 102 (2005) 9253-9257
69. + T cells following peptide vaccination. J. Immunol. 176 (2006) (in press)
70. Odunsi K., Jungbluth A.A., Stockert E., Qian F., Gnjatic S., Tammela J., Intengan M., Beck A., Keitz B., Santiago D., Williamson B., Scanlan M.J., et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 63 (2003) 6076-6083
71. Ono T., Kurashige T., Harada N., Noguchi Y., Saika T., Niikawa N., Aoe M., Nakamura S., Higashi T., Hiraki A., Wada H., Kumon H., et al. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc. Natl. Acad. Sci. USA 98 (2001) 3282-3287
72. Park J.H., Kong G.H., and Lee S.W. hMAGE-A1 overexpression reduces TNF-alpha cytotoxicity in ME-180 cells. Mol. Cells 14 (2002) 122-129
73. Peng J.R., Chen H.S., Mou D.C., Cao J., Cong X., Qin L.L., Wei L., Leng X.S., Wang Y., and Chen W.F. Expression of cancer/testis (CT) antigens in chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett. 219 (2005) 223-232
74. Prasad M.L., Jungbluth A.A., Patel S.G., Iversen K., Hoshaw-Woodard S., and Busam K.J. Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck. Head Neck 26 (2004) 1053-1057
75. Qian F., Gnjatic S., Jager E., Santiago D., Jungbluth A., Grande C., Schneider S., Keitz B., Driscoll D., Ritter G., Lele S., Sood A., et al. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. Cancer Immun. 4 (2004) 12
76. Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., et al. The DNA sequence of the human X chromosome. Nature 434 (2005) 325-337
77. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 (1995) 1151-1164
78. Satie A.P., Rajpert-De Meyts E., Spagnoli G.C., Henno S., Olivo L., Jacobsen G.K., Rioux-Leclercq N., Jegou B., and Samson M. The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ. Lab. Invest. 82 (2002) 775-780
79. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102 (2005) 18538-18543
80. Scanlan M.J., Simpson A.J., and Old L.J. The cancer/testis genes: Review, standardization, and commentary. Cancer Immun. 4 (2004) 1
81. Schultz-Thater E., Noppen C., Gudat F., Durmuller U., Zajac P., Kocher T., Heberer M., and Spagnoli G.C. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br. J. Cancer 83 (2000) 204-208
82. Shackleton M., Davis I.D., Hopkins W., Jackson H., Dimopoulos N., Tai T., Chen Q., Parente P., Jefford M., Masterman K.A., Caron D., Chen W., et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4 (2004) 9
83. Sharma P., Gnjatic S., Jungbluth A.A., Williamson B., Herr H., Stockert E., Dalbagni G., Donat S.M., Reuter V.E., Santiago D., Ritter G., Chen Y.T., et al. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun. 3 (2003) 19
84. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T., and Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5 (2005) 615-625
85. Slager E.H., Borghi M., van der Minne C.E., Aarnoudse C.A., Havenga M.J., Schrier P.I., Osanto S., and Griffioen M. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: A tumor antigen translated in an alternative open reading frame. J. Immunol. 170 (2003) 1490-1497
86. Slager E.H., van der Minne C.E., Kruse M., Krueger D.D., Griffioen M., and Osanto S. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J. Immunol. 172 (2004) 5095-5102
87. Smith C.L., Mirza F., Pasquetto V., Tscharke D.C., Palmowski M.J., Dunbar P.R., Sette A., Harris A.L., and Cerundolo V. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified Vaccinia Ankara. J. Immunol. 175 (2005) 8431-8437
88. Stockert E., Jäger E., Chen Y.-T., Scanlan M.J., Gout I., Karbach J., Arand M., Knuth A., and Old L.J. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187 (1998) 1349-1354
89. Sugita M., Geraci M., Gao B., Powell R.L., Hirsch F.R., Johnson G., Lapadat R., Gabrielson E., Bremnes R., Bunn P.A., and Franklin W.A. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res. 62 (2002) 3971-3979
90. Sugita Y., Wada H., Fujita S., Nakata T., Sato S., Noguchi Y., Jungbluth A.A., Yamaguchi M., Chen Y.T., Stockert E., Gnjatic S., Williamson B., et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. 64 (2004) 2199-2204
91. Tajima K., Obata Y., Tamaki H., Yoshida M., Chen Y.T., Scanlan M.J., Old L.J., Kuwano H., Takahashi T., Takahashi T., and Mitsudomi T. Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer 42 (2003) 23-33
92. Türeci O., Sahin U., Zwick C., Koslowski M., Seitz G., and Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc. Natl. Acad. Sci. USA 95 (1998) 5211-5216
93. Valmori D., Dutoit V., Liénard D., Rimoldi D., Pittet M.J., Champagne P., Ellefsen K., Sahin U., Speiser D., Lejeune F., Cerottini J.C., and Romero P. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 60 (2000) 4499-4506
94. Valmori D., Dutoit V., Ayyoub M., Rimoldi D., Guillaume P., Lienard D., Lejeune F., Cerottini J.C., Romero P., and Speiser D.E. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 3 (2003) 15
95. van der Bruggen P., Traverseri C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., and Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1650
96. van Rhee F., Szmania S.M., Zhan F., Gupta S.K., Pomtree M., Lin P., Batchu R.B., Moreno A., Spagnoli G., Shaughnessy J., and Tricot G. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105 (2005) 3939-3944
97. Vaughan H.A., Svobodova S., Macgregor D., Sturrock S., Jungbluth A.A., Browning J., Davis I.D., Parente P., Chen Y.T., Stockert E., St Clair F., Old L.J., et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin. Cancer Res. 10 (2004) 8396-8404
98. Wang H.Y., Lee D.A., Peng G., Guo Z., Li Y., Kiniwa Y., Shevach E.M., and Wang R.F. Tumor-specific human CD4+ regulatory T cells and their ligands: Implications for immunotherapy. Immunity 20 (2004) 107-118
99. Wang R.F., Johnston S.L., Zeng G., Topalian S.L., Schwartzentruber D.J., and Rosenberg S.A. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161 (1998) 3598-3606
100. Wang Y., Liang Z., Yuan Y.H., Han Y., Liu Y.X., Liu N., Chen Y.T., Ritter G., Old L.J., and Zhang L.J. Expression of multiple cancer-testis antigen genes in non-small cell lung cancer treated by chemotherapy prior surgery. Zhonghua Yi Xue Za Zhi 84 (2004) 464-468
101. Wang Y., Wu X.J., Zhao A.L., Yuan Y.H., Chen Y.T., Jungbluth A.A., Gnjatic S., Santiago D., Ritter G., Chen W.F., Old L.J., and Ji J.F. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun. 4 (2004) 11
102. Weber J., Salgaller M., Samid D., Johnson B., Herlyn M., Lassam N., Treisman J., and Rosenberg S.A. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res. 54 (1994) 1766-1771
103. Xing B.C., Yuan Y.H., Hu Z.G., Liu Y.X., Han Y., Liu N., Chen W.F., and Wang Y. Expression of NY-ESO-1/LAGE-1 genes in hepatocellular carcinoma and autologous humoral responses induced thereby. Zhonghua Yi Xue Za Zhi 84 (2004) 1980-1982
104. Zarour H.M., Storkus W.J., Brusic V., Williams E., and Kirkwood J.M. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 60 (2000) 4946-4952
105. Zarour H.M., Maillere B., Brusic V., Coval K., Williams E., Pouvelle-Moratille S., Castelli F., Land S., Bennouna J., Logan T., and Kirkwood J.M. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 62 (2002) 213-218
106. Zeng G., Touloukian C.E., Wang X., Restifo N.P., Rosenberg S.A., and Wang R.F. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 165 (2000) 1153-1159
107. Zeng G., Wang X., Robbins P.F., Rosenberg S.A., and Wang R.F. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. USA 98 (2001) 3964-3969
108. Zeng G., Aldridge M.E., Wang Y., Pantuck A.J., Wang A.Y., Liu Y.X., Han Y., Yuan Y.H., Robbins P.F., Dubinett S.M., deKernion J.B., and Belldegrun A.S. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker. Int. J. Cancer 114 (2005) 268-273
109. Zhang W.M., Xiao G., Xie D., Zhang M., Guo A.L., and Wen J.M. Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma. Ai Zheng 24 (2005) 622-626